

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
December 12, 2022**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**2seventy bio, Inc.**

**File No. 1-40791 - CF#35609**

2seventy bio, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information Bluebird bio, Inc. excluded from the Exhibits to a Form 10-Q filed on November 1, 2017.

Based on representations by 2seventy bio, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.19                      through November 1, 2032

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Dana Hartz  
Chief, Knowledge Management Office